GlassScriptPhysician profile
Muhammad Sohail Mansoor
NPI 1225383797
$2,858.37
in general payments reported to CMS, 2019-2025
18 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $112 · 2021: $218 · 2022: $86.99 · 2023: $584 · 2024: $711 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.36 | 2019-2025 | |
| Janssen Biotech, INC. | $516.12 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $315.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $196.96 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.52 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $157.31 | 2025 | |
| Medtronic, INC. | $155.78 | 2021-2025 | Interstim |
| Regeneron Pharmaceuticals, INC. | $142.15 | 2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $130.71 | 2023-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2023 | Zeposia |
| Lilly USA, LLC | $91.99 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $91.71 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $89.32 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $55.07 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $43.51 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $21.08 | 2025 | Suflave, Sutab |
| Pfizer INC. | $16.65 | 2025 | |
| Evoke Pharma, INC. | $14.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mansoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.